GSK Sees Light At End Of Shingrix Tunnel As COVID-19 Eases
Company Records Steep Sales Decline For Shingles Vaccine in Q1
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.
You may also be interested in...
Influenza and pneumococcal vaccine sales were initially strong at the start of the pandemic. Recent weak revenues for travel, childhood and premium vaccines could raise population immunity concerns, however.
Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.
Caught in a ‘vaccine nationalism’ crossfire a year ago, CureVac is now well placed to become a commercial entity – just as long as its mRNA platform can deliver.